

Vaccines and Global Health: The Week in Review 25 October 2025 :: Issue 819 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

Milestones, Perspectives

:::::::

Health Emergencies – Country Guidance

WHO launches new country guidance for health emergency coordination

23 October 2025 Departmental update

...Health emergencies are becoming more frequent and complex, driven by factors such as climate change, urbanization, geopolitical shifts, and increased global mobility. This new guidance equips national and subnational authorities with the tools and strategies needed for a rapid, coordinated, multi-sectoral response, which is essential to minimize suffering and death at times of crisis.

The framework brings together the core components of the Health Emergency Preparedness, Resilience and Response (HEPR) architecture, which integrated over 300 recommendations following the COVID-19 pandemic. Intended for government authorities and all stakeholders involved in health emergency response, it provides practical tools like checklists and flowcharts, referencing existing guidance from WHO and partners.

The framework outlines the different stages of a health emergency, from detection and notification to risk assessment, activation of emergency procedures, response interventions, and operational review. It also promotes the integration of performance evaluation into response for different hazards, and introduces timelines for the completion of key activities for both outbreaks and disasters, building on the **7-1-7 evaluation framework, which sets performance targets of 7 days to detect an outbreak, 1 day to notify public health authorities, and 7 days to complete early response actions.**

This new guidance is part of WHO's work in strengthening national capacity for emergency response. By providing a consistent and unified framework, the new guidance enables countries to better respond to any health emergency at any scale.




Figure 1. The HEPR architecture integrates over 300 recommendations for health emergency preparedness and response following the COVID-19 pandemic, across governance, financing and five core systems.




Figure 4. Functions within a health response under an IMS. These can be reduced or expanded as required.

[Editor's box highlight of vaccination]

:::::::

Editor's Note:

We include the announcement below from last week's edition as it aligns with and supports the above.

WHO upgrades its public health intelligence system to boost global health security 13 October 2025 News release

Today, the World Health Organization (WHO), in collaboration with key partners and supporters, launched version 2.0 of the Epidemic Intelligence from Open Sources (EIOS) system, used globally for the early detection of public health threats. Since its development in 2017, the initiative has grown steadily and is now being used by more than 110 Member States and around 30 organizations and networks around the world.

The update incorporates new data sources and improved functionalities, including the use of artificial intelligence (AI). Hosted at the WHO Hub for Pandemic and Epidemic Intelligence in Berlin, EIOS is the world's leading initiative for open-source intelligence for public health decision-making. It helps public health teams detect and respond to potential threats daily by analyzing large volumes of publicly available information in near real time...

Recent health emergencies, such as the COVID-19 pandemic, and the mpox and avian influenza outbreaks, have demonstrated how critical early detection is to prevent outbreaks from escalating into global crises. **With version 2.0, public health experts around the globe are now better**

equipped to quickly identify new health threats and monitor ongoing events, whether they are linked to conflict, climate change, or new and re-emerging pathogens...

WHO offers the EIOS system as a public good, free of charge to its Member States and eligible organizations and supports them with training and communities of practice. Ministries of Health and public health agencies use the EIOS system to complement information they receive through formal channels, such as laboratories and hospitals. The EIOS system enables them to identify relevant content from websites, social media and other public sources to identify important health events, which authorities can then verify and assess...

.....

NTDs

Global report on neglected tropical diseases 2025

WHO 22 October 2025

PDF: https://iris.who.int/server/api/core/bitstreams/9c4655d8-3671-4503-ae51-4a80bb44d5e0/content Overview

In 2025, the WHO Global Neglected Tropical Diseases Programme marks 20 years of action and data. Since its establishment in 2005, a concerted effort involving pharmaceutical manufacturers, development partners, philanthropic organizations, national health authorities and WHO has contributed to a measurable decline in the global burden of neglected tropical diseases (NTDs).

This report presents progress made in 2023–2024 towards the 2030 targets set in *Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021-2030* (the road map), including several **important analytical updates:**

- Progress on all overarching, cross-cutting and disease-specific indicators, milestones and targets.
- Analysis of disease burden in terms of disability-adjusted life years (DALYs), prevalence and mortality, as well as numbers of people affected by NTDs, detected and treated.
- New perspectives on the financial risk associated with NTDs, highlighting their impoverishing effects on affected populations.
- A detailed review of four thematic areas diagnostics, monitoring and evaluation, access and logistics, and advocacy and funding enabled by the Gap Assessment Tool (GAT).

...5. Conclusions and way forward [p.104]

Concerted action over the past 20 years has established NTDs as a powerful global advocacy brand that has transformed support for under-recognized illnesses into a coordinated global movement for equity in health. The growing list of countries eliminating NTDs through a combination of strategic interventions, strong political commitment and community engagement is a powerful testament of what is achievable.

This report highlights a wealth of progress and substantial public health gains made to-date. NTDs are gaining traction in national health agendas and sustainability planning. There has even been scale-up for some of the interventions against NTDs in the post COVID-19 scenario.


Yet, these successes are fragile and threatened by existential factors. Climate change continues to expand vector-borne NTDs into new areas. Geopolitical conflicts, migration, humanitarian crises and instability disrupt access to NTD interventions and may further compromise equity. Data gaps and incomplete surveillance systems continue to undermine strategic planning and routine programme management. Importantly, without funding mechanisms that


empower country ownership and beneficiary community engagement, there is a real risk of stagnation or even reversal of hard-won gains.

All efforts should continue to be made to improve efficiencies and harness synergies within and beyond NTD programmes. Programme operations should prioritize integration, harness the immense potential of digital tools and mobilize domestic resources, community engagement and ownership as keys to amplifying the effectiveness of the multifaceted strategic approaches presented in the road map.

Adapting to the pervasive budgetary crises that NTD programmes are facing requires continuation of the shift from vertical, donor-driven models to sustainable, integrated and country-led approaches, as advocated in the road map. By improving efficiency, fostering collaboration and building stronger country ownership, NTD programmes can stay on track to meet the 2030 road map targets despite the financial constraints. This calls for stronger coordination practices at all levels of programme delivery, and more accurate reflection of the contribution of NTDs to the broader goals of universal health coverage, primary health care and the SDGs.

Keeping NTDs visible and present on the global agenda is critical to regaining and sustaining momentum towards elimination targets and protecting vulnerable communities. The political commitment expressed in the road map to 2030 must be amplified and demonstrated through synergistic actions, at all levels, that can accelerate progress towards attaining set targets with numerous benefits across health, economic, social and development sectors.





Data source: WHO/Global Health Observatory

Polio - PHEIC

Polio this week [22 October 2025]

Headlines

::::::::

:: Bill Gates: "We're closer than ever to eradicating polio... and closer than ever to seeing a resurgence."

In this <u>post</u>, Bill Gates explains why the world is closer than ever to eradicating polio, and why a global funding gap leaves the world vulnerable to a resurgence.

:: World Polio Day 2025 - A Global Call to Finish the Job

24 October marks World Polio Day, a chance for the global community to come together to renew commitment to ending one of humanity's longest-running public health efforts. Led by Rotary International, Rotarians and partners around the world organize events, campaigns, and discussions to raise awareness and resources for the final push to eradicate polio — once and for all. <u>More</u>.

...:: GPEI partners in Africa set key actions for 2026

Health leaders from across Africa gathered in Nairobi last week to take stock of progress and chart a bold path forward for ending all remaining poliovirus transmission on the continent. The high-level meeting, convened by the Global Polio Eradication Initiative (GPEI), focused on intensifying operations in the last remaining areas where variant polioviruses continue to circulate, and ensuring that Africa's hard-won gains are fully sustained. More.

Summary of new polioviruses this week:

- :: Afghanistan: two WPV1 cases and eleven WPV1-positive environmental samples
- :: Papua New Guinea: two cVDPV2 cases

::::::::

Selected Events

Models of Global Collaboration: Practical Approaches to Vaccine Access and Governance

Global Health Coffee Session, Harvard Global Health Institute Friday, October 31, 2025

9:00 AM - 10:00 AM ET Virtual

Speakers

Juliet Nabyonga-Orem, MBChB, MSc, PhD

Health Systems Advisor, Participatory Governance & Policy, WHO Namibia

William K. Ampofo, PhD

Executive Director, Africa Vaccine Manufacturing Initiative

:::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

::::::::

WHO & Regional Offices [25 Oct 2025]

https://www.who.int/news Selected News/Announcements/Statements 24 October 2025 Departmental update

<u>Countries, regulators and partners urge a collaborative approach to advance safe and</u> equitable AI in health

The Outcome Statement from AIRIS Incheon 2025 calls for:

- a lifecycle-based regulatory approach spanning medical product development, clinical trials, manufacturing, evaluation and post-market surveillance;
- risk-proportionate regulation tailored to national contexts and health system needs;
- stronger international collaboration to close gaps between countries and foster a trustworthy global AI ecosystem; and
- sustained global governance through AIRIS as a regular platform for dialogue among regulators, international organizations and technical partners.

24 October 2025 Departmental update

<u>Strengthening global public health through traditional medicine: 3rd World Congress on Traditional, Complementary and Integrative Medicine</u>

23 October 2025 Departmental update

WHO launches new country guidance for health emergency coordination

23 October 2025 Departmental update

MERS-CoV virus isolate added to the WHO BioHub System, enabling further research and pandemic preparedness

22 October 2025 Departmental update

WHO and partners refine global map of tools for assessing Science Advisory Systems

On 14 August 2025, WHO and the University of Antioquia's Unit of Evidence and Deliberation for Decision Making (UNED) convened international experts to advance a new global Evidence and Gap Map (EGM) on science advisory systems. The consultation is part of a broader WHO initiative to help countries strengthen national science advice systems to enhance public health and contribute to economic growth...

22 October 2025 Departmental update

Global progress against neglected tropical diseases continues despite challenges, new WHO report finds

22 October 2025 Departmental update

Strengthening Indigenous-led engagement in global health and biodiversity governance

...The 'Ottawa Dialogue on Traditional Knowledge, Biodiversity and Health: Restoring Trust, Strengthening Partnerships, and Advancing Indigenous-Led Pathways' brought together 25 participants, including Indigenous Elders, knowledge holders, community leaders, researchers, policy-makers, medical practitioners and UN representatives. It was hosted by the World Health Organization (WHO), in collaboration with Indigenous Peoples' Centre for Documentation, Research and Information (Docip), the Ărramăt Project and Tinhinan Canada Association. The event marked a key step in co-developing WHO's forthcoming Framework on Indigenous Knowledge, Biodiversity and Health, coordinated through the WHO Global Traditional Medicine Centre and the WHO Environment, Climate Change and One Health Department...

.....

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1 Updates Events

6 November 2025 11:00 - 15:00 SAST

<u>Together for a TB-free world: Financing and access solutions for novel tuberculosis</u> vaccines

The Government of South Africa and WHO are co-organizing a high-level side event, "Together for a TB-free world: Financing and access solutions for novel TB vaccines," on the sidelines of the G20 Health Ministers Meeting.

:::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 23 October 2025

National poliovirus sequencing capacity enhances Cameroon's outbreak response

:: 21 October 2025

Cholera outbreak declining in Congo

WHO Region of the Americas PAHO

:: 23 Oct 2025

<u>PAHO highlights 31 years without polio in the Americas and calls to strengthen vaccination</u> efforts

Despite the Americas being certified polio-free in 1994, only 83% of children received the third dose of the polio vaccine in 2024 — well below the 95% needed to prevent outbreaks. Washington, D.C., October 23, 2025 (PAHO) — On World Polio Day (October 24), the Pan American Health Organization (PAHO) celebrates over three decades without wild...

:: 22 Oct 2025

COP30 in Belém: PAHO recommends yellow fever and measles vaccination for travelers

Washington, D.C., October 22, 2025 (PAHO/WHO) – Ahead of the 30th United Nations Climate Change Conference (COP30), scheduled for November 10–21, 2025, in Belém, Pará state, Brazil, the Pan American Health Organization/World Health Organization (PAHO/WHO) is recommending that travelers — including heads of state, scientists, activists, and civil...

:: 20 Oct 2025

PAHO publishes guide for designing Artificial Intelligence instructions in public health

Washington D.C., October 20, 2025 (PAHO) – The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts. The publication aims to promote the responsible use of AI to...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 24 October 2025 News release

World Polio Day: vaccination remains key to keeping Europe polio free

:: 24 October 2025 News release

Polio response in Ukraine strengthened, as local laboratories receive WHO accreditation

WHO Eastern Mediterranean Region EMRO

:: EU Increases humanitarian funding to expand WHO's health response in Afghanistan

WHO Western Pacific Region

:: 24 October 2025 Media release

WHO Western Pacific Member States take action on key health priorities

:: 23 October 2025 Feature story

No Child Left Behind: PNG's Fight Against Polio

:: 23 October 2025 *Media release*

<u>Western Pacific countries and areas join forces to prevent cross-border health</u> <u>emergencies</u>

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

:::::::

Weekly Epidemiological Record

Vol. 100, No. 42, pp. 469-482 17 October 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

:: Recommended composition of influenza virus vaccines for use in the 2026 southern hemisphere influenza season

[No new issue identified]

:::::::

New WHO Publications

https://www.who.int/publications

Selected

23 October 2025

National health emergency alert and response framework

Overview

This multi-hazard Health Emergency Alert and Response Framework provides guidance for coordinating emergency response in countries, under the global Health Emergency Preparedness, Resilience and Response (HEPR) framework. It outlines the public health functions, coordination systems and actions needed for effective local, sub-national and national response to a broad range of health emergencies, including disasters. The audience for this framework is the primary national and sub-national authorities with the designated responsibility for health emergency coordination.

22 October 2025

<u>21th edition, Epidemiological Bulletin WHO Health Emergencies Programme WHO Regional Office for South-East...</u>

22 October 2025

Global nutrition targets 2030: topical briefs on maternal, infant and young child nutrition

22 October 2025

Global report on neglected tropical diseases 2025

Africa

Africa CDC [25 Oct 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

Press Releases

<u>Charting a pathway toward self-reliance: 4th International Conference on Public Health in</u>
Africa (CPHIA) Opens in Durban, South Africa

23 October 2025

... The conference spotlights African-led innovations, policy solutions, and research aimed at building resilient and self-reliant health systems, tailored to the needs of citizens across the continent. Hosted by the Africa Centres for Disease Control and Prevention (Africa CDC) and co-organised with the Government of South Africa and AfricaBio's BIO Africa Convention, the opening ceremony brought together local, regional, and global delegates, including ministers of health, leading scientists, youth leaders, and civil society.

More than 20 countries are expected to converge in Durban, including representatives from global agencies such as the African Union Commission, the World Health Organisation, UNICEF, Gavi, and the Global Fund, among others...

::::::

China - CDC+

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [25 Oct 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [25 Oct 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-10-24 / No. 43

PDF of this issue

- <u>Vital Surveillances: Epidemiological Characteristics and Spatiotemporal Clustering Analysis of Human Rabies China, 2005–2024</u>
- <u>Vital Surveillances: Genomic Characterization of Human Adenovirus Type 21 Strains 7 PLADs,</u>
 China, 2023–2024

- <u>Preplanned Studies: Detection of Dengue Virus RNA in Breast Milk Following Peripartum Infection Guangzhou City, Guangdong Province, China, 2024</u>
- <u>Preplanned Studies: Prospective Study on Clinical Performance of Host DNA Methylation Assay for Triage in Women Who Are HPV-Positive 4 Provinces, China, 2018–2021</u>

::::::

Europe

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

<u>Local transmission of clade 1b mpox cases detected in EU/EEA, ECDC urges renewed vigilance</u>

24 Oct 2025

ECDC urges immunisation and other measures as Europe enters respiratory virus season 20 Oct 2025

Assessment

Threat Assessment Brief: Detection of autochthonous transmission of monkeypox virus clade Ib in the EU/EEA

24 Oct 2025

This Threat Assessment Brief aims to assess the risk of autochthonous transmission of monkeypox virus (MPXV) clade Ib in EU/EEA countries in the context of male-to-male sexual transmission. It is intended for public health authorities in EU/EEA countries and is based on currently available evidence.

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news

News & Press Releases

ICMRA Summit 2025: EMA concludes its two mandates as chair

ICMRA elects new chair in Amsterdam

24 October 2025

......

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare Announcements

No new digest content identified.

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external

analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.

White House, HHS, FDA, CDC+

White House

<u>Presidential Actions – Executive Orders; Memoranda; Proclamations</u> No new digest content identified.

Department of State

<u>Press Releases</u> - Selected No new digest content identified.

HHS

<u>Press Room</u> - Selected No new digest content identified.

NIH

http://www.nih.gov/ News Releases - Selected No new digest content identified.

FDA

<u>Press Announcements</u> - Selected No new digest content identified.

FDA CBER

Latest News

Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers - October 2025

GUIDANCE DOCUMENT - Final Level 1 Revised Guidance 10/22/2025

This guidance provides information for industry, researchers, physicians, institutional review boards, and patients about the implementation of FDA's regulations on expanded access to investigational drugs for treatment use under an investigational new drug application (21 CFR part 312, subpart I), which went into effect on October 13, 2009. FDA received numerous questions concerning implementation of the regulatory requirements for expanded access. As a result, FDA issued the guidance for industry Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers (June 2016, updated October 2017), providing recommendations in a question-and-answer format, addressing the most frequently asked questions. Since 2017, FDA has received additional questions concerning implementation of the regulatory and statutory requirements of expanded access to investigational drugs, including those added by the 21st Century Cures Act and the FDA Reauthorization Act of 2017.

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee October 9, 2025</u>
<u>Meeting Announcement - 10/09/2025</u>
<u>Event Materials</u>

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

<u>Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments</u>

A Notice by the Food and Drug Administration on 10/02/2025

DATES: The meeting will be held on virtually on **November 13, 2025**, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET). Comments: November 5, 2025

CDC

http://www.cdc.gov/media/index.html Latest News - Selected No new digest content identified.

CDC – Immunization Safety Office (ISO)

https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html No new digest content identified.

ACIP

2026 Meetings Schedule

- February 25-26
- June 24-25
- October 21-22

Vaccine, Volume 67, 20 November 2025, 127876

Commentary

Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes

Edwin J. Asturias ^a, Lin H. Chen ^b, Albert C. Shaw ^c, Charlotte A. Moser ^d, Yvonne A. Maldonado ^e, Jane R. Zucker ^f, Helen Y. Chu ^g, H. Keipp Talbot ^h, Sybil Cineas ⁱ, Karyn Lyons ^j, Robert Schechter ^k, Mini Kamboj ^l, Zanthia Wiley ^m, Noel T. Brewer ⁿ *Abstract*

Background

Since 1964, the Advisory Committee on Immunization Practices (ACIP) has shaped US vaccine policy but recently underwent significant structural and procedural changes affecting recommendation quality. This paper presents analyses of the September 2025 ACIP meeting by former ACIP voting members.

Methods

We examined ACIP policymaking maturity using a standardized tool for assessing national vaccine advisory groups' development and functionality. We also analyzed evidence presented, processes, and vaccine recommendations.

Results

Between April and September 2025, ACIP's policymaking maturity rating fell from an overall score of 100 % to 58 %. The September meeting had multiple transparency violations, including the exclusion of liaison organizations with medical expertise in vaccine implementation before the meeting. Poorly framed policy questions were followed by a lack of systematic application of standard protocols (e.g., GRADE methodology and Evidence to Recommendations framework). The committee voted to recommend shared clinical decision making for COVID-19 vaccines, to limit access to combined first dose MMRV vaccines, and to postpone voting on removing the birth dose of hepatitis B vaccine. Discussions reflected poor understanding of process, inadequate grasp of science, and a focus on low-quality safety data, excluding well-recognized components and standards for vaccine policy making.

Conclusions

Four concerns have emerged that limit ACIP's ability to make effective vaccine policy recommendations for the US: 1) removal of choice for previously recommended

vaccines, thereby limiting opportunities to improve health, 2) focus on theoretical vaccine harms using low-quality data, 3) loss of vaccine science and clinical practice expertise, and 4) reduced transparency and independence.

MMWR Weekly

https://www.cdc.gov/mmwr/index2025.html

September 25, 2025 / No. 36

No new edition identified.

National Vaccine Program Committee (NVAC)

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

https://www.hrsa.gov/advisory-committees/vaccines/meetings

Next ACCV Meeting - TBD [To be re-scheduled from original date January 29, 2025]

:::::::

NSF

News

No new digest content identified.

:::::::

U.S. Congress

House of Representatives

No new digest content identified.

U.S. Senate

Senate Health, Education, Labor, and Pensions (HELP) Committee

No new digest content identified.

::::::::

Supreme Court, Federal & Appellate Courts

No new digest content identified.

.....

U.S. States

No new digest content identified.

U.S. Medical Societies, Health Organizations

American Academy of Pediatrics (AAP)

https://www.aap.org/en/news-room/news-releases-from-the-aap/

(Accessed 04 Sep 2025)

News

No new digest content identified.

American College of Physicians (ACP)

https://www.acponline.org/more-acp-news

(Accessed 04 Sep 2025)

ACP News

New ACP toolkit helps members navigate potential vaccine policy changes

10/22/25

ACP Advocate

[!Requires ACP membership for access]

Infectious Diseases Society of America (IDSA)

https://www.idsociety.org/

(Accessed 04 Sep 2025)

News releases and statements

News

Shingles Vaccine Lowers Risk of Dementia, Major Cardiovascular Events

Being vaccinated against shingles decreased the risk of heart disease, dementia and death in people age 50 and older.

Last Updated October 19, 2025

News

RSV Immunization in Infants Is Safe and Provides High Antibody Levels Regardless of Mother's Vaccination Status

Immunization against RSV is safe and effective in both infants and mothers, regardless of the mother's RSV vaccination status.

Last Updated October 19, 2025

American Public Health Association (APHA)

https://www.apha.org/news-and-media/news-

<u>releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc</u>

(Accessed 04 Sep 2025)

News Releases

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

https://www.smfm.org/

(Accessed 04 Sep 2025)

News

No new digest content identified.

Massachusetts Public Health Alliance (MPHA)

https://mapublichealth.org/press-room/

(Accessed 04 Sep 2025)

Press Room

No new digest content identified.

American Medical Association (AMA)

https://www.ama-assn.org/press-center

(Accessed 04 Sep 2025)

Press Center

No new digest content identified.

American Academy of Family Physicians (AAFP)

https://www.aafp.org/news/media-center.html (Accessed 04 Sep 2025) Statements, Releases No new digest content identified.

American Geriatrics Society (AGS)

https://www.americangeriatrics.org/media-center (Accessed 04 Sep 2025) Recent Press Releases No new digest content identified.

American Osteopathic Association (AOA)

https://osteopathic.org/news/
(Accessed 04 Sep 2025)

Latest News
No new digest content identified.

National Medical Association (NMA)

https://nmanet.org/blog/ (Accessed 04 Sep 2025) Latest News No new digest content identified.

National Foundation for Infectious Diseases (NFID)

https://www.nfid.org/news-updates/ (Accessed 04 Sep 2025) News and Updates October 20, 2025

Why We Give Hepatitis B Vaccines to Infants

For nearly 40 years, hepatitis B vaccination has been recommended for US infants to prevent hepatitis B infection, which can lead to liver damage, failure, and cancer

October 21, 2025

Staying on Track: Evidence-Based Vaccine Recommendations

Looking for trusted vaccine guidance? Read on for evidence-based immunization recommendations from professional medical groups and trusted NFID partners ...

Looking for trusted vaccine guidance? The National Foundation for Infectious Diseases (NFID) provides clear and accurate information about the prevention and treatment of infectious diseases. Read on for evidence-based immunization recommendations from professional medical groups and trusted NFID partners ...

American Academy of Family Physicians (AAFP): AAFP provides immunization schedules based on age to prevent serious diseases, with specific recommendations for <u>children from birth</u> through age 18 years, and separate schedules for adults based on age and medical conditions.

<u>American Academy of Pediatrics (AAP)</u>: AAP has published an independent evidence-based <u>immunization schedule</u> for children and adolescents. The AAP schedule includes guidance

on <u>COVID-19 vaccination</u> that differs from current federal policy. It also includes updates to recommendations on <u>respiratory syncytial virus (RSV)</u> and <u>influenza (flu)</u>:

- **COVID-19**—recommended for all children ages 6-23 months and for older children in certain risk groups, based on evidence on who can benefit the most from the vaccine
- **Flu**—recommends annual flu vaccination for all children starting at age 6 months, unless they have a medical reason not to be immunized
- RSV-recommends RSV vaccine during pregnancy or RSV immunization (nirsevimab or clesrovimab) for infants whose mothers were not vaccinated during pregnancy

"AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," <u>said</u> AAP President Susan J. Kressly, MD. "Pediatricians know how important routine childhood immunizations are in keeping children, families, and their communities healthy and thriving."

<u>American College of Cardiology (ACC)</u>: ACC has issued <u>Concise Clinical Guidance (CCG)</u> recommending certain vaccines to help protect heart health. The guidance includes detailed evidence for each vaccine recommendation and answers to frequently asked questions to guide conversations between patients and healthcare professionals. Vaccine specific recommendations include:

- **COVID-19**—recommended for adults with heart disease to help reduce their risk of infection and protect against severe illness, hospitalization, and death. Vaccination helps protect against heart attack, COVID-19-induced pericarditis/myocarditis, COVID-19-induced stroke and atrial fibrillation (irregular heartbeat), and long COVID symptoms.
- **Flu**—recommends annual flu vaccine for all adults to help prevent flu and lower the risk of serious complications and death. Nasal versions of the vaccine are not recommended in patients age 50 years or older.
- **Pneumococcal Disease**—recommended for adults age 19 years or older with heart disease to help protect against pneumonia, bacteremia, and meningitis and reduce the risk of hospitalization and death
- RSV-single dose recommended for adults age 75 or older and for adults age 50–74 with heart disease to help protect against lower respiratory disease that can result in hospitalization and death
- **Shingles**—recommended for adults age 50 or older to receive 2 doses to protect against increased risk of stroke and heart attack when infected. People with heart disease are at an increased risk of shingles infection.

American College of Obstetricians and Gynecologists (ACOG): ACOG released updated clinical guidance regarding vaccination during pregnancy against COVID-19, flu, and RSV. The 3 guidance documents, all of which recommend maternal immunization, lay out the full body of current scientific evidence that underscores the safety and benefits of choosing to be vaccinated against these respiratory conditions during pregnancy.

- COVID-19—COVID-19 Vaccination Considerations for Obstetric—Gynecologic Care
 recommends that patients receive an updated COVID-19 vaccine at any point during
 pregnancy, when planning to become pregnant, in the postpartum period, or when
 breastfeeding.
- **Flu**—<u>Influenza in Pregnancy: Prevention and Treatment</u> strongly recommends that all individuals who are or will be pregnant during flu season receive an inactivated or recombinant flu vaccine as soon as it is available, during any trimester of pregnancy. ACOG recommends flu vaccination before the start of flu season but encourages vaccination at any time during the season to ensure protection as long as flu is circulating in the community.
- **RSV**–<u>RSV</u>, <u>Maternal Respiratory Syncytial Virus Vaccination</u>, recommends that maternal RSV vaccine during pregnancy in order to protect the infants after birth. Patients should

also understand that if they decline the maternal RSV vaccination, their infant needs a monoclonal antibody at birth.

"It is well documented that respiratory conditions can cause poor outcomes during pregnancy, with pregnant women facing both severe illness and threats to the health of their pregnancy. Thanks to vaccines, severe outcomes from respiratory infections are largely preventable," said Steven J. Fleischman, MD, MBA, president of ACOG. "ACOG's updated respiratory guidance documents repeat what we have long known: that vaccines continue to be the best tool available for pregnant patients to protect themselves and their infants from these viruses."

<u>Infectious Diseases Society of America (IDSA)</u>: IDSA has released new COVID-19 vaccination guidelines recommending that all adults and children who are immunocompromised receive an age-appropriate COVID-19 vaccine for the 2025-2026 season. The group recommends that patients talk with their healthcare professionals about the timing and other clinical considerations specific to their individual situations.

People who are immunocompromised include individuals with impaired immune systems due to disease (such as cancer or HIV) or medications they must take to treat a health condition (for example, for organ transplantation). The guidelines also advise that household members and those in close contact with individuals who are immunocompromised be up to date with COVID-19 vaccination to provide further protection.

"Vaccines are one of the most powerful tools to prevent respiratory viral illnesses, and this protection is especially important for individuals in our communities who have impaired immune systems," said Lindsey Robert Baden, MD, vice president of clinical research at Mass General Brigham, and chair of the guideline panel. "IDSA's guideline for COVID vaccination for individuals who are immunocompromised helps protect people who often suffer the most severe associated illnesses."

IDSA will release additional recommendations on flu and RSV vaccination for individuals who are immunocompromised.

ID will continue to update th			

::::::::

Civil Society – Individuals, Organizations, Institutions

:::::::

Kaiser Family Foundation/KFF [25 Oct 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

U.S. Foreign Aid Freeze & Dissolution of USAID: Timeline of Events

Oct 24, 2025

Feature

This timeline provides a detailed overview of actions, including counter-actions, related to the administration's efforts to freeze all U.S. foreign aid and dissolve the U.S. Agency for International Development (USAID).

Last entry in timeline:

September 26, 2025

Supreme Courts grants a partial stay on the preliminary injunction in GHC v. Trump and AVAC v. State Department.

On September 26, the Supreme Court <u>granted</u> the administration's request to partially stay the September 3rd preliminary injunction as it pertained to funds included in the <u>President's proposed rescissions package</u>, in the GHC v. Trump and AVAC v. State Department cases.

Overview of President Trump's Executive Actions on Global Health

Oct 24, 2025

Fact Sheet

This guide provides an overview of executive orders and other executive actions made by the Trump Administration since January 21, 2025 that directly address or affect U.S. global health efforts. This resource identifies each executive action, describes its purpose and actions taken, and outlines the implications and what happens next for each. The resource will be updated as needed.

:::::::

Vaccine Integrity Project - CIDRAP

https://www.cidrap.umn.edu/vaccine-integrity-project

Vaccine Integrity Project - Response to HHS claims about vaccines (Oct 2025)

Oct 22, 2025 Video – YouTube: 5:51

Dr. Michael Osterholm, from the University of Minnesota's Center for Infectious Disease Research and Policy (CIDRAP) and the Vaccine Integrity Project, addresses misinformation about vaccines, particularly in a previously shared video by Health and Human Services Secretary Robert F. Kennedy Jr.

<u>Summary of findings - Updated Evidence for 2025-2026 Covid-19, RSV, and Influenza Immunizations (October 21 2025)</u>

Kev Findinas

- Covid-19, RSV, and influenza continue to cause substantial morbidity and mortality across all age groups in the United States
- This systematic review synthesized 511 studies published since the most recent ACIP Evidence-to-Recommendation reviews (2023-2024), examining vaccine effectiveness and safety data for U.S.licensed immunizations
- Current evidence continues to demonstrate that immunizations are associated with meaningful reductions in hospitalization and severe outcomes across populations, with reassuring safety profiles consistent with prior evaluations

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [25 Oct 2025]

https://alleninstitute.org/news-press/

Featured

<u>Lab Notes | Bridging science fiction and reality: Seattle Hub for Synthetic Biology</u> Oct 20, 2025

Global science lies at the edge of a new age of discovery thanks to advances in synthetic biology driving innovations that could reshape human health.

News

<u>Susan Kaech, Ph.D., named next leader of Allen Institute's Immunology moonshot</u> Oct 21, 2025

Leader in immunology to advance the Institute's next frontier in understanding the immune system's role across health and disease

BMGF - Gates Foundation [25 Oct 2025]

https://www.gatesfoundation.org/ideas/media-center Press Releases & Statements No new digest content identified.

CARB-X [25 Oct 2025]

https://carb-x.org/

News

No new digest content identified.

Chan Zuckerberg Initiative [25 Oct 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [25 Oct 2025]

http://cepi.net/ CEPI News, Blog No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 25 Oct 2025]

https://cioms.ch/

News; Publications; Events No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [25 Oct 2025]

https://www.darpa.mil/news

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [25 Oct 2025]

https://dndi.org/press/press-releases/

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [25 Oct 2025]

https://dukeghic.org/

News

No new digest content identified.

EDCTP [25 Oct 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [25 Oct 2025]

http://www.vaccines.emory.edu/

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [25 Oct 2025]

http://www.euvaccine.eu/

News

No new digest content identified.

Fondation Merieux [25 Oct 2025]

http://www.fondation-merieux.org/

Actualités

No new digest content identified.

Gates Medical Research Institute [25 Oct 2025]

https://www.gatesmri.org/news

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications No new digest content identified.

Gavi [to 25 Oct 2025] https://www.gavi.org/ News Releases No new digest content identified.

GE2P2 Global Foundation [25 Oct 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

Digests

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 03 Oct 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest May 2025

GHIT Fund [25 Oct 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 25 Oct 2025]

https://www.theglobalfund.org/en/news/

News Releases

20 October 2025

Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed a new £6 million investment by GSK plc (LSE/NYSE: GSK) and ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as ...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [25 Oct

2025]

https://www.glopid-r.org/

News & Events

No new digest content identified.

Hilleman Laboratories [25 Oct 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [25 Oct 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [25 Oct 2025]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [25 Oct 2025]

https://www.iavi.org/

Press Releases, Features

IAVI Report

Dedication, not defeat

October 23, 2025

Drastic cuts to U.S. government funding imperil HIV/AIDS treatment and prevention programs and threaten HIV vaccine and cure research efforts across Africa. But the overarching view from East African researchers is one of resilience, not defeat.

IAVI Report

'Of all the moments for science to slow down, this is not it.'

October 23, 2025

An HIV vaccine academy showcases the scientific talent of African researchers but is tempered by funding worries

INSERM [25 Oct 2025]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 25 Oct 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selected]

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025 Swissmedic, Switzerland - Deadline for comments by 30 November 2025 TFDA, Chinese Taipei - Deadline for comments by 13 October 2025 USA, FDA, Deadline 12/01 2025 **Docket No. FDA-2025-D-3023**

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe) Date of Step 2b: 25 June 2025 Status: Step 3

Ongoing Public Consultations	
> M13B EWG Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
> Q1 EWG Stability Testing of Drug Substances and Drug Products	
> M4Q(R2) EWG Revision of M4Q(R1)	
> Q3E EWG Guideline for Extractables and Leachables	
> E20 EWG Adaptive Designs for Clinical Trials	

https://www.ich.org/page/public-consultations

ICRC [to 25 Oct 2025]

https://www.icrc.org/en/news

News

<u>ICRC president: Global IHL initiative testament to what is possible when states choose humanity over self-interest</u>

Statement 23-10-2025

23-10-2025

Haiti: making impossible choices in a health-care system on the verge of collapse

IFFIm [25 Oct 2025] http://www.iffim.org/

Press Releases/Announcements

Georgina Baker appointed Chair of the International Finance Facility for Immunisation Board

London, 22 October 2025 – The International Finance Facility for Immunisation (IFFIm) today announced the appointment of Georgina Baker as Chair of its Board of Directors, effective 1 January 2026. Ms Baker succeeds Ken Lay, who has led the Board since 2021 and will continue to serve as a Director through 2026 to ensure a smooth transition and cont...

IFRC [to 25 Oct 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [25 Oct 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

Institut Pasteur [25 Oct 2025]

https://www.pasteur.fr/en/press-area

Press Documents

24.10.2025

<u>Study suggests two unsuspected pathogens struck Napoleon's army during the retreat</u> from Russia in 1812

Scientists from the Institut Pasteur have genetically analyzed the remains of former soldiers who retreated from Russia...

ISC / International Science Council [to 25 Oct 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

news

No new digest content identified.

International Union of Immunological Societies (IUIS)

https://iuis.org/ News, Resources

IUIS 2025 Congress Recordings Now Available on ImmunoHub

September 30, 2025

IVAC [25 Oct 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [25 Oct 2025]

http://www.ivi.int/

IVI News & Announcements

No new digest content identified.

Johns Hopkins Center for Health Security [25 Oct 2025]

https://centerforhealthsecurity.org/newsroom

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 25 Oct 2025]

https://www.rwjf.org/en/about-rwjf/newsroom.html

Latest News and Highlights No new digest content identified.

MSF/Médecins Sans Frontières [to 25 Oct 2025]

http://www.msf.org/

Latest [Selected Announcements]

Gaza-Israel war

People's health is direly impacted by poor living conditions in Gaza despite ceasefire

24 Oct 2025

Gaza-Israel war

MSF has resumed activities in Gaza City

23 Oct 2025

Democratic Republic of Congo

Cholera epidemic in Democratic Republic of Congo is increasingly worrying

22 Oct 2025

National Academy of Medicine - USA [to 25 Oct 2025]

https://nam.edu/programs/ News, Stories, Insights No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 25 Oct 2025]

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

PATH [25 Oct 2025]

https://www.path.org/media-center/

Newsroom [Selected]

No new digest content identified.

Sabin Vaccine Institute [25 Oct 2025]

https://www.sabin.org/press/

Latest News & Press Releases

2026 Gold Medal and Rising Star Award Nominations are Open

October 21, 2025

UNAIDS [25 Oct 2025]

http://www.unaids.org/en

News, Stories, Updates

Press Release

South Africa charts a new frontier by rolling out a twice-yearly injection which is almost 100% effective in preventing HIV

Germany steps up support to UNAIDS amidst HIV funding crisis

23 October 2025

UNICEF [to 25 Oct 2025]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements [Selected]

Remarks 24 October 2025

<u>"Sudan is the world's largest humanitarian crisis - and children are paying the highest price"</u>

N'DJAMENA/NEW YORK 24 October 2025, — "Thank you for joining us. I speak to you a day after leaving Darfur, following a mission that also took me to Khartoum. "What I saw was alarming. Sudan is the world's largest humanitarian crisis. The conflict is escalating, and children are paying the highest price.

Press release 23 October 2025

IOM, UNHCR, UNICEF and WFP urge immediate action to address escalating humanitarian crisis in Sudan

GENEVA/NEW YORK/ROME/PORT SUDAN, 23 October 2025 –, Four United Nations agencies today called for urgent international attention on the crisis in Sudan, to address the immense suffering and growing dangers to the population. Over 900 days of brutal fighting, widespread violations of human rights, famine, and the b...

Unitaid [25 Oct 2025]

https://unitaid.org/ Press Releases News releases

<u>Unitaid to improve access to diagnostics through integrated tools and delivery approaches</u> <u>with new call for proposals</u>

23 October 2025

News releases

<u>Unitaid launches new funding opportunity to heat-proof health products ahead of COP30</u> 21 October 2025

Vaccine Equity Cooperative [nee Initiative] [25 Oct 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

Vaccine Confidence Project [25 Oct 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified. http://www.chop.edu/centers-programs/vaccine-education-center

News

October 2025 - Hepatitis B Vaccine Birth Dose and Separating MMR

Check out two videos in which Dr. Paul Offit discusses vaccines in the news: hepatitis B vaccine birth dose and separating MMR vaccine into individual components.

Wellcome Trust [25 Oct 2025]

https://wellcome.org/news/all News. Opinion, Reports Researcher story Author Dr Mo Yin

How collaboration can help tackle drug-resistant infections

21 October 2025

The Wistar Institute [to 25 Oct 2025]

https://www.wistar.org/news/press-releases

Press Releases
October 21, 2025

<u>First-in-Human Study of DNA Antibody Replicas Generate Efficient and Long-Lasting Biologic Production of Human Antiviral Antibodies</u>

A multidisciplinary team of scientists led by The Wistar Institute published today in Nature Medicine a breakthrough in biologic antibody production that happens directly in human subjects in this en...

World Bank [25 Oct 2025]

http://www.worldbank.org/en/news/all

All News [Selected]

Unlivable: Confronting Extreme Urban Heat in Latin America and the Caribbean

Download the Report Latin America and the Caribbean face a new climate reality: rising temperatures, more frequent heatwaves, and record-breaking extremes. The number of extremely hot days—those above the...

Date: October 20, 2025 Type: Publication

WFPHA: World Federation of Public Health Associations [25 Oct 2025]

https://www.wfpha.org/

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 06 Sep 025]

https://www.wma.net/news-press/press-releases/

Press Releases

The World Medical Association General Assembly 2025 in summary

21st October 2025

The 76th General Assembly of the World Medical Association, held in Porto, Portugal, from 8–11 October 2025, brought together delegates from 54 National Medical Associations to address urgent issues facing the medical profession today.

Adoption of key WMA policies and governance items

The General Assembly adopted a <u>comprehensive package of new and revised policies</u>, reflecting the collective consensus of the global medical profession on issues central to ethics, workforce, and patient care.

In total, 21 policies and two governance documents were adopted, while several existing policies were reaffirmed with minor revisions.

The declarations, resolutions and statements adopted or updated by the WMA General Assembly include:

WMA Statement on Artificial and Augmented Intelligence in Medical Care

WMA Statement on Ethical Guidelines for the International Migration of Physicians (revised)

WMA Statement on Physician Mental Health Care

WMA Statement on Scope of Practice, Task Sharing and Task Shifting (revised)

WMA Statement on the Protection of Reproductive Health Rights of Women and Girls

WMA Statement on Trans People (revised)

WMA Resolution Calling on the Israeli Government to Comply with the Geneva Conventions and Other Applicable Instruments of Humanitarian Law

WMA Resolution on Health Workforce at the World Health Organisation (WHO)

World Organisation for Animal Health [OIE] [25 Oct 2025]

https://www.oie.int/ Press Releases, Statements No new digest announcements identified.

::::::

ARM [Alliance for Regenerative Medicine] [25 Oct 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest announcements identified.

BIO [25 Oct 2025]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [25 Oct 2025]

http://www.dcvmn.org/ News; Upcoming events

DCVMN Annual General Meeting 2025

October 29 - 31, 2025

Bali, Indonesia

ICBA – International Council of Biotechnology Associations [25 Oct 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [25 Oct 2025]

https://ifpma.org/

Statement 21 Oct 2025

76th Session of the WHO Regional Committee for the Western Pacific on "Implementing the International Health Regulations (2005) amendments"

On 21 October 2025 in Nadi, Fiji, IFPMA delivered a statement at the 76th Session of the WHO Regional Committee for the Western Pacific on "Implementing the International Health Regulations (2005) amendments." We commend the Western Pacific Region for its engagement to develop priority actions for countries and areas in the region to utilize the...

International Alliance of Patients' Organizations – IAPO [25 Oct 2025]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [25 Oct 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified.

Bavarian Nordic

<u>Latest News</u> - No new digest announcements identified.

BioCubaFarma - Cuba

<u>Últimas Noticias</u> - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases

22 October 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Boehringer

<u>Press Releases</u> - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News

Oct 20, 2025

Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

CSL Sequirus

News Releases

Cell-Based Flu Vaccines Offer 20% More Protection

21 Oct 2025

- Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the prevention of test-confirmed influenza during the 2023/24 U.S. season for populations six months to 64 years. [1]
- Consistent rVE results were observed for pediatric, adult, outpatient and high-risk subgroups. [1]
- This latest RWE represents the fifth season of large retrospective test-negative studies showing greater protection of cell-based influenza vaccines relative to standard egg-based influenza vaccines, elevating the standard of care for influenza prevention for pediatrics six months and older and adults up to and including 64 years. [1]

Curevac

News - No new digest announcements identified.

Dailchi Sankyo

<u>Press Releases</u> - No new digest announcements identified.

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

GSK's Shingrix new prefilled syringe presentation receives positive CHMP opinion 20 October 2025

- :: Prefilled syringe offers a convenient ready-to-use administration option to healthcare professionals :: Marketing authorisation in EU expected in December 2025
- :: Shingles affects approximately 1.7 million people in Europe each year1

Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment

20 October 2025

EuBiologics, S Korea

News - Website not responding at inquiry.

HIPRA

<u>Press releases</u> - No new digest announcements identified.

IMBCAMS, China

<u>Home</u> - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

<u>Press Releases</u> - No new digest announcements identified.

Merck

News releases

Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults

October 21, 2025

Findings presented at IDWeek 2025 underscore the importance of considering serotypes that disproportionately impact adults in the U.S. and show greater resistance to commonly prescribed antibiotics

Merck Breaks Ground on \$3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

October 21, 2025

Nanogen

News - No new digest announcements identified.

Novartis

<u>News</u> - No new digest announcements identified.

Novavax

Press Releases

Oct 22, 2025

Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy

- :: Agreements signed to transfer one U.S.-based facility and sell certain equipment netting \$60 million in cash and resulting in future cash savings of \$230 million
- :: Novavax headquarters to remain in Gaithersburg, Md.

Pfizer

<u>Recent Press Releases</u> - No new digest announcements identified.

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

<u>Press Releases</u>

October 20, 2025

<u>Press Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose</u>

Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and over

Serum Institute

<u>News & Announcements</u> - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

<u>Press Releases</u> - No new digest announcements identified.

SK Biosciences

<u>Press Releases</u> - No new digest announcements identified.

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 3 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 10: E713-767 Oct 2025

https://journalofethics.ama-assn.org/issue/diagnostic-research

Diagnostic Research

What exactly is a medical mystery? Any one condition of illness could be diagnosed, misdiagnosed, a missed diagnosis, undiagnosed, or perhaps something else. The National Institutes of Health (NIH) defines undiagnosed diseases as "long-standing symptoms or elusive medical conditions that have not been diagnosed despite extensive clinical evaluation." What is now known as the Undiagnosed Diseases Network (UDN) was a research study first established by the NIH in 2008 and is now funded by the National Institute of Neurological Disorders and Stroke. Its charge is to convene experts, conduct research on human subjects at 14 US clinic locations, forge new knowledge, and "solve the most challenging medical mysteries." UDN research subjects must apply with supporting documentation from their clinicians and health records. Fewer than half of UDN applicants are enrolled in a protocol, and, among subjects evaluated by clinician-investigators, some receive a diagnosis. This theme issue considers a range of neglected diagnostic research ethics questions and investigates ethics questions about UDN policies, practices, and public support.

American Journal of Human Genetics

Oct 02, 2025 Volume 112 Issue 10 p2251-2562

https://www.cell.com/ajhg/current

This month in *The Journal*

Paul W. Hook, Alyson B. Barnes

Obesity and obesity-related traits have a major impact on global health. While a myriad of genes and variants have been associated with these traits, substantial functional work still needs to be performed to understand the underlying molecular mechanisms. In this issue, Baya et al. identify genes associated with obesity and fat distribution using exome sequencing from the UK Biobank and test their function in a human adipocyte cell line. Using rare variant gene burden tests, the authors find 69 genes associated with traits, including body mass index (BMI), waist-to-hip ratio adjusted for BMI, and body fat percentage.

[Reviewed earlier]

American Journal of Infection Control

October 2025 Volume 53 Issue 10 p1023-1130 http://www.ajicjournal.org/current **Special Issue: Hand Hygiene**

[Reviewed earlier]

American Journal of Preventive Medicine

October 2025 Volume 69 Issue 4 https://www.ajpmonline.org/current [Reviewed earlier]

American Journal of Public Health

October 2025 115(10)

http://ajph.aphapublications.org/toc/ajph/current

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 3 (Sep 2025)

https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-3.xml

[Reviewed earlier]

Annals of Internal Medicine

October 2025 Volume 178, Issue 10

https://www.acpjournals.org/toc/aim/current

Original Research

<u>Aluminum-Adsorbed Vaccines and Chronic Diseases in Childhood - A Nationwide Cohort</u> Study

Niklas Worm Andersson, MD, PhD, Ingrid Bech Svalgaard, MSc, Stine Skovbo Hoffmann, MD, PhD ... et al.

Pages:1369-1377

Abstract

Background:

Aluminum is used as an adjuvant in nonlive vaccines administered in early childhood. Concerns persist about potential associations between vaccination with aluminum-adsorbed vaccines and increased risk for chronic autoimmunity, atopy or allergy, and neurodevelopmental disorders. Large-scale safety data remain limited.

Objective:

To assess the association between cumulative aluminum exposure from early childhood vaccination and risk for autoimmune, atopic or allergic, and neurodevelopmental disorders.

Design:

A cohort study linking nationwide registry data on childhood vaccinations, outcome diagnoses, and potential confounders, leveraging the variations in the aluminum content of childhood vaccines over time.

Setting:

Denmark, 1997 to 2020.

Participants:

1 224 176 children born in Denmark between 1997 and 2018 who were alive and residing in the country at age 2 years.

Intervention:

Cumulative aluminum amount received (per 1-mg increase) through vaccination during the first 2 years of life.

Measurements:

Incident events of 50 chronic disorders, including autoimmune (dermatologic, endocrinologic, hematologic, gastrointestinal, and rheumatic), atopic or allergic (asthma, atopic dermatitis, rhinoconjunctivitis, and allergy), and neurodevelopmental (autism spectrum disorder and attention deficit—hyperactivity disorder).

Results:

Cumulative aluminum exposure from vaccination during the first 2 years of life was not associated with increased rates of any of the 50 disorders assessed. For groups of combined outcomes, adjusted

hazard ratios per 1-mg increase in aluminum exposure were 0.98 (95% CI, 0.94 to 1.02) for any autoimmune disorder, 0.99 (CI, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (CI, 0.90 to 0.97) for any neurodevelopmental disorder. For most individually analyzed outcomes, the upper bounds of the 95% CIs were incompatible with relative increases greater than 10% or 30%. Limitation:

Individual medical records were not reviewed.

Conclusion:

This nationwide cohort study did not find evidence supporting an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines. For most outcomes, the findings were inconsistent with moderate to large relative increases in risk, although small relative effects, particularly for some rarer disorders, could not be statistically excluded.

Primary Funding Source:

None.

Position Papers

Bolstering the Medication Supply Chain and Ameliorating Medication Shortages: A Position Paper From the American College of Physicians

Josh Serchen, MPP, David Hilden, MD, MPH and Jenny R. Silberger, MD, for the ... et al.

Pages:1464-1468

Ideas and Opinions

The U.S. Advisory Committee on Immunization Practices: Public Health in the Crosshairs
Jason Goldman, MD and Robert Hopkins, MD

Pages:1497-1498

...This dismantling of a rigorous process to guide vaccine policy is evidence that the United States has come to a point where politics, not science, is driving some important health care policies. Rather than evidence, manipulated and biased disinformation is driving decision making and policies that are likely to result in adverse outcomes for Americans. Science should have no agenda except seeking knowledge unfettered by bias. True scientists seek factual answers to questions, regardless of whether the data yield the expected or desired answer. It is unacceptable to distort data or ignore evidence that does not align with one's belief system or political agenda. We are all entitled to our own opinions, but not to our own "facts." The "new ACIP" has done exactly what the director of the Department of Health and Human Services wrongly accused the previous committee of doing: hiding data, promoting a political agenda, acting as a rubber stamp, and voting on recommendations when potential conflicts of interest were present (10)...

Artificial Intelligence – An International Journal

Volume 347 October 2025

https://www.sciencedirect.com/journal/artificial-intelligence/vol/346/suppl/C

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 25 Oct 2025) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content

(Accessed 25 Oct 2025 [No new digest content identified]

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 25 Oct 2025)

Real world effectiveness of antipneumococcal vaccination against pneumonia in adults: a population-based cohort study, Catalonia, 2019

Despite recognised benefits against vaccine-type pneumococcal infections, limited and inconsistent evidence exists on the effectiveness of pneumococcal vaccination in preventing pneumococcal and all-cause pneu...

Authors: Cinta de Diego-Cabanes, Verònica Torras-Vives, Angel Vila-Córcoles, Eva M. Satué-Gracia, M. José Forcadell-Peris, Frederic Gómez-Bertomeu, Leonardo de Esteban-Júlvez, Imma Hospital-Guardiola,

Cruz M. Fuentes-Bellido, Anna Ribes-Alcover, Clara Rodriguez-Casado and Olga Ochoa-Gondar

Citation: BMC Infectious Diseases 2025 25:1369

Content type: Research Published on: 21 October 2025

<u>Physicians' knowledge of, and willingness to encourage caregivers to partake in the RTS S/ASO1 and R21 matrix M malaria vaccines roll out – a national survey in Nigeria</u>

The malaria parasite, caused by Plasmodium falciparum, continues to pose serious public health threats in tropical and sub-tropical regions of the world, despite the availability of malaria vaccine. Since Octo...

Authors: Mary Aigbiremo Oboh, Olumide Thomas Adeleke, Oludamola Victoria Adeleke and Titilope

Abisola Awotunde

Citation: BMC Infectious Diseases 2025 25:1345

Content type: Research Published on: 17 October 2025

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content (Accessed 25 Oct 2025) [No new digest content identified]

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 25 Oct 2025) No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 25 Oct 2025) No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles (Accessed 25 Oct 2025)

<u>Hepatitis B vaccination status and associated factors among people living with HIV in Gulu, Uganda: a cross-sectional study</u>

Hepatitis B vaccination is highly recommended among people with HIV (PWH) because they have a poor prognosis when infected with Hepatitis B virus (HBV). Among PWH, HBV infection s are more likely to progress t...

Authors: Maria Nakabuye, Ivan Segawa, Kevin Ouma Ojiambo, George William Ndagga, Ponsiano

Ocama and Pauline Byakika-Kibwika Citation: *BMC Public Health* 2025 25:3572

Content type: Research Published on: 22 October 2025

<u>Cost effectiveness of female HPV vaccines for routine childhood immunisation schedule in</u> Türkive

To evaluate the cost-effectiveness of introducing Human Papillomavirus (HPV) vaccination into Türkiye's National Immunization Program.

Authors: Çağrı Emin Şahin and Selma Karabey Citation: BMC Public Health 2025 25:3561

Content type: Research Published on: 21 October 2025

<u>Strategies and challenges for immunisation of children under 5 years in primary health</u> care in different countries: a scoping review

This study mapped the strategies used by PHC to immunise children under 5 years of age, as well as identifying challenges in achieving vaccine coverage in accordance with goals set by countries' national immun...

Authors: Camila Amaral Moreno Freitas, Ana Luiza Queiroz Vilasbôas and Nília Maria de Brito Lima

Prado

Citation: BMC Public Health 2025 25:3558

Content type: Research Published on: 21 October 2025

Barriers and facilitating factors for COVID-19 vaccination in rural Appalachia

Since the onset of the pandemic, COVID-19 mortality has disproportionately impacted populations impacted by health inequities. This study aimed to identify the barriers and facilitators to COVID-19 vaccination...

Authors: Kathryn M. Cardarelli, Rachel Gillespie, Anna Goodman Hoover, Diane B. Francis and Marc T.

Kiviniemi

Citation: BMC Public Health 2025 25:3545

Content type: Research Published on: 21 October 2025

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 25 Oct 2025) [No new digest content identified]

BMJ Evidence-Based Medicine

October 2025 - Volume 30 - 5 https://ebm.bmj.com/content/30/5 [Reviewed earlier]

BMJ Global Health

October 2025 - Volume 10 - 10 https://gh.bmj.com/content/10/10 [Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - September 2025 https://thebulletin.org/magazine/2025-09/#post-heading [Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 10, October 2025, 577-640 https://www.who.int/publications/journals/bulletin/ [Reviewed earlier]

Cell

Oct 02, 2025 Volume 188 Issue 20 p5433-5784 https://www.cell.com/cell/current [Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4 https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4 [Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 6 November 2025 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 4 Pages: 749-966 October 2025 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current [Reviewed earlier]

Clinical Therapeutics

October 2025 Volume 47 Issue 10 p827-956 http://www.clinicaltherapeutics.com/current [Reviewed earlier]

Clinical Trials

Volume 22 Issue 5, October 2025 https://journals.sagepub.com/toc/ctja/22/5 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/

[Accessed 25 Oct 2025]
[No new digest content identified]

Contemporary Clinical Trials

Volume 157 October 2025 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/157/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 5 / October 2025 https://www.liebertpub.com/toc/crispr/8/5 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025 https://link.springer.com/journal/40142/volumes-and-issues/13-1 [Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

October 2025 - Volume 38 - Issue 5 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx PAEDIATRIC AND NEONATAL INFECTIONS [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 25 Oct 2025] [No new digest content identified]

Cytotherapy

October 2025 Volume 27 Issue 10 p1151-1270 https://www.isct-cytotherapy.org/current [Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 3 Pages: 165-252 September 2025 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025 https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 49, Issue 4 October 2025 https://onlinelibrary.wiley.com/toc/14677717/current **Future of humanitarian and development aid**[Reviewed earlier]

eBioMedicine

Volume 119 September 2025 https://www.sciencedirect.com/journal/ebiomedicine/vol/119/suppl/C [Reviewed earlier]

EMBO Reports

Volume 26 Issue 198 October 2025 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 10—October 2025 http://wwwnc.cdc.gov/eid/ [New issue; No digest content identified]

Epidemics

Volume 52 September 2025 https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 5 Pages: 1-43 September–October 2025 https://onlinelibrary.wiley.com/toc/25782363/current

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 2 - Summer 2025

https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue

Roundtable: Global Governance in Hard Times

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 4, August 2025 https://academic.oup.com/eurpub/issue/35/4 [Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

November/December 2025 Volume 104, Number 6 https://www.foreignaffairs.com/issues/2025/104/5 [Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

http://www.tandfonline.com/toc/sfds20/current

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities
[Reviewed earlier]

Frontiers in Genetics

https://www.frontiersin.org/journals/genetics

[Accessed 25 Oct 2025]

Frontiers in Genome Editing

https://www.frontiersin.org/journals/genome-editing

[Accessed 25 Oct 2025] Published on 20 Oct 2025

Editorial: Genome editing for climate change adaptation in agriculture: innovations,

applications, and regulatory considerations

Koppolu Raja Rajesh Kumar, Prashant Kumar Singh doi 10.3389/fgeed.2025.1711767

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463

[Accessed 25 Oct 2025]

[No new digest content identified]

Gene Therapy - Nature

Volume 32 Issue 5, October 2025 https://www.nature.com/gt/volumes/32/issues/5

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 25 Oct 2025] [No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/

 $\frac{\text{https://www.loc.gov/books/?q=legal+reports\&fa=partof\%3Alegal+reports+\%28publications+of+the+legal+reports}{\text{aw+library+of+congress\%29\&sb=date}}$

[Accessed 25 Oct 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/

[Accessed 25 Oct 2025]

China's COVID-19 aid in Africa: trends and implications for future pandemic preparedness

Chronic underfunding of pandemic preparedness remains a critical weakness in global health security. Without sustained, strategic investment, the world risks repeating the reactive approaches of past crises. T...

Authors: Julia Hudson, Raghav Venkataramani, Sailor Miao and Julius N. Odhiambo

Citation: Globalization and Health 2025 21:59

Content type: Research Published on: 24 October 2025

Abstract Background

Chronic underfunding of pandemic preparedness remains a critical weakness in global health security. Without sustained, strategic investment, the world risks repeating the reactive approaches of past crises. This study examines the modes of COVID-19 aid delivered by the Chinese government across African countries and regions, offering a nuanced understanding of China's operational role in pandemic response. In doing so, it contributes to the global health assistance literature by providing a more comprehensive view of China's involvement in the prevention, treatment, and control of COVID-19.

Results

Analysis of 727 Chinese health-related project commitments to African countries indicates that the majority targeted the provision of personal protective equipment (43.33%), followed by diagnostic and medical equipment (26%), and vaccination initiatives (17.88%). Regionally, Southern Africa received the highest average number of projects per country, while Northern Africa received the lowest. At the national level, South Africa (5.09%), Zimbabwe (4.00%), and Cameroon (3.85%) accounted for the largest shares of total projects, whereas Eritrea (0.001%), Cabo Verde (0.004%), and Somalia (0.004%) received the smallest proportions.

Conclusions

This research reveals the growing significance of Chinese aid in the global health agenda through its active role in combating COVID-19 across the African continent. It also highlights emerging trends and suggests potential adjustments needed in pandemic financing strategies for more effective future efforts.

Health and Human Rights

Volume 27, Issue 1, June 2025

https://www.hhrjournal.org/volume-27-issue-1-june-2025/

SPECIAL SECTION - FIGHT FOR RIGHTS VIEWPOINT SERIES

Health Economics, Policy and Law

Volume 20 - Issue 3 - July 2025 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 8, September 2025 https://academic.oup.com/heapol/issue/40/8 [Reviewed earlier]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 25 Oct 2025] [No new digest content identified]

Human Gene Therapy

Volume 36, Issue 17-18 / September 2025 https://www.liebertpub.com/toc/hum/36/17-18 [Reviewed earlier]

Humanitarian Practice Network

https://odihpn.org/ [Accessed 25 Oct 2025] Featured Publications [No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025 https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList Selected Content [Reviewed earlier]

Immunity

Sep 09, 2025 Volume 58 Issue 9 p2139-2354 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 25 Oct 2025] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content]

[Accessed 25 Oct 2025]
[No new digest content identified]

International Health

Volume 17, Issue 5, September 2025 https://academic.oup.com/inthealth/issue/17/5 [Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025) https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml [Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 9 (2025): September 2025 https://www.ijcmph.com/index.php/ijcmph/issue/view/128 [Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025 https://academic.oup.com/ije/issue/54/3 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 3 4 September 2025 https://www.emerald.com/ijhrh/issue/18/3 *Table of contents*[Reviewed earlier]

JAMA

October 21, 2025, Vol 334, No. 15, Pages 1313-1404 https://jamanetwork.com/journals/jama/currentissue [New issue; No digest content identified]

JAMA Health Forum

October 2025, Vol 6, No. 10 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

October 2025, Vol 179, No. 10, Pages 1051-1136 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

October 2025 - Volume 23 - Issue 10 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

October 2025 Volume 77 Issue 4 p587-796 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025) https://www.jair.org/index.php/jair [Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025 https://link.springer.com/journal/11673/volumes-and-issues/22-1 [Reviewed earlier]

Journal of Community Health

Volume 50, Issue 5 October 2025 https://link.springer.com/journal/10900/volumes-and-issues/50-5 Articles [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025 https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C [Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 4, October 2025 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

September 2025 - Volume 79 - 9 https://jech.bmj.com/content/79/9 [Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 3 September 2025 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 2 (2025) http://www.tandfonline.com/toc/rjge20/current [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 3, August 2025 https://muse.jhu.edu/issue/55342 Table of Contents [Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 4 August 2025 https://link.springer.com/journal/10903/volumes-and-issues/27-4 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 3 (2025) https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 37, Issue 7 Pages: 1-1567 October 2025 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 53 - Issue 3 - Fall 2025 https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue
Public Health, Markets, and Law
[Reviewed earlier]

Journal of Medical Ethics

October 2025 - Volume 51 - 10 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

The Journal of Pediatrics

Volume 284 September 2025 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1 https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList [Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2025 - Volume 31 - Issue 5 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 3 September 2025 https://link.springer.com/journal/41271/volumes-and-issues/46-3 [Reviewed earlier]

Journal of the Royal Society – Interface

October 2025 Volume 22 Issue 231 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 6, August 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Oct 25, 2025 Volume 406 Number 10514 p1923-2032 https://www.thelancet.com/journals/lancet/issue/current

Drug pricing and pharmaceutical innovation: a false promise

The Lancet

Oct 05, 2024 Volume 404 Number 10460 p1279-1374 Correspondence

An urgent case for measles vaccination in Gaza

Ronald Waldman, Robert Steinglass, Phillip Nieburg

In response to the identification of circulating vaccine-derived poliovirus type 2 in wastewater in Gaza, followed by a single confirmed case of paralytic poliomyelitis in a young child, the first round of an oral polio vaccination campaign targeting children (aged ≤ 10 years) is underway and has, as of Sept 16, 2024, been highly successful. The detailed planning, hard work, and heroic dedication of all those involved, under the most trying of circumstances, are evident. A second round of vaccination is planned for the end of September, 2024. Now that an operational platform is in place, we believe that the second round should include vaccination against measles, which has consistently been the deadliest vaccine-preventable disease in humanitarian emergencies.

Measles is among the most highly infectious diseases known and is symptomatic in nearly 100% of exposed, non-immune individuals. High population density, inadequate shelter, poor sanitation, and undernutrition are all major risk factors for infection, severity, and death, and all are features of the deplorable conditions for those people living in Gaza. The imminent arrival of cooler temperatures adds to the urgency to vaccinate against this disease, which can cause the death of up to 15% of those infected.2

As with poliovirus, reported vaccination coverage for measles has been high in Gaza, but has been falling. With the collapse of the health-care system, many children being vaccinated against measles within the past year is unlikely. Treatment of complications of measles will be difficult, if not impossible. Due to the very rapid rate of transmission and the dangerous environment, vaccinating after an outbreak occurs might be too late—prevention is by far the best, if not the only, life-saving measure.

Unlike poliovirus, the measles vaccine is delivered by injection. However, the delivery of vaccines by both oral and injectable routes has been done successfully in the past when conflicts have been temporarily paused to allow children to be vaccinated. Since the current polio vaccination campaign is operating from multiple fixed sites and not house-to-house, the delivery of measles vaccine to a restricted target population (possibly children aged 6–23 months) is feasible with some additional training of staff in triage, crowd control, risk communication, and safe injection techniques. Those involved in organising and implementing the current vaccination campaign (such as Gazan health authorities, UN agencies, and non-governmental organisations) are justified in restricting the focus of the current operation. Under the circumstances, any unwarranted expansion or add-on of unnecessary interventions can result in operational complications that could jeopardise the outcome. There is good reason that, for nearly 50 years, mass measles vaccination campaigns have become a standard early intervention in conflict and other humanitarian settings; 3,4 the risk of a measles outbreak and accompanying high mortality is just too great. As Steinglass and colleagues 5 have stated, to forgo measles vaccination of the children of Gaza would be a failure to learn from the past, a missed opportunity, and risks leading to an unacceptable public health tragedy.

The Lancet Child & Adolescent Health

Oct 2025 Volume 9 Number 10 p685-752 https://www.thelancet.com/journals/lanchi/issue/current

[Reviewed earlier]

Lancet Digital Health

Sep 2025 Volume 7 Number 9 https://www.thelancet.com/journals/landig/issue/current [New issue; No digest content identified]

Lancet Global Health

Oct 2025 Volume 13 Number 10 e1654-e1780 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Sep 2025 Volume 25 Number 9 p947-1054, e491-e541 https://www.thelancet.com/journals/laninf/issue/current Articles
[Reviewed earlier]

Lancet Public Health

Oct 2025 Volume 10 Number 10 e804-e88 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Oct 2025 Volume 13 Number 10 p857-950, e53-e55 https://www.thelancet.com/journals/lanres/issue/current [New issue; No digest content identified]

Maternal and Child Health Journal

Volume 29, Issue 10 October 2025 https://link.springer.com/journal/10995/volumes-and-issues/29-10 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 7, October 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 3 Pages: 639-939 September 2025 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Oct 01, 2025 Volume 33 Issue 10 p4657-5282 https://www.cell.com/molecular-therapy/current In this issue

The advent of mRNA vaccines has revolutionized vaccine development, offering a swift and versatile development platform. One advantage possessed by mRNA vaccines is the ability to express antigens in soluble/secreted forms or transmembrane (TM) forms, which can better mimic the native viral envelope (Env) protein. Previous research has indicated some improvements in immune responses with the use of a TM Env trimer immunogen over the use of a secreted antigen, but the picture of the impact of TM antigens on the full immune response has remained incomplete.

Nature

Volume 646 Issue 8086, 23 October 2025 https://www.nature.com/nature/volumes/646/issues/8086 [New issue; No digest content identified]

Nature Biotechnology

Volume 43 Issue 10, October 2025 https://www.nature.com/nbt/volumes/43/issues/10 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 25 Oct 2025)
[Reviewed earlier]

Nature Genetics

Volume 57 Issue 10, October 2025 https://www.nature.com/ng/volumes/57/issues/10 [Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 10, October 2025 https://www.nature.com/nathumbehav/volumes/9/issues/10 [New issue; No digest content identified]

Nature Medicine

Volume 31 Issue 10, October 2025 https://www.nature.com/nm/volumes/31/issues/10 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 10, October 2025 https://www.nature.com/nrd/volumes/24/issues/10

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 10, October 2025 https://www.nature.com/nrg/volumes/26/issues/10 [Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 10, October 2025 https://www.nature.com/nri/volumes/25/issues/1 [Reviewed earlier]

New England Journal of Medicine Volume

Volume 393 No. 16 October 23, 2025 https://www.nejm.org/toc/nejm/medical-journal Original Articles

Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans

M. Cai, Y. Xie, and Z. Al-Aly

In this national cohort of U.S. veterans, the receipt of the 2024–2025 Covid-19 vaccine was associated with decreased risks of severe clinical outcomes. (Funded by the Department of Veterans Affairs.)

NEJM Evidence

Volume 4 No. 9 September 2025 https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

nip Vaccines

https://www.nature.com/npjvaccines/ [Accessed 25 Oct 2025] [No new digest content identified]

Pediatrics

Volume 156, Issue 4 October 2025 https://publications.aap.org/pediatrics/issue/156/3 [Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 10 October 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-10 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 25 Oct 2025) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 25 Oct 2025) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 25 Oct 2025)

<u>Caregivers' practices and factors associated with malaria vaccine uptake among under-five children in the Tiko Health District, Cameroon: A community based cross-sectional study</u>
Idang Maureen Abiache, Divine Nsobinenyui, Chrisantus Eweh Ukah, Yunika Larissa Kumenyuy, Ngu Claudia Ngeha, Randolf Wefuan, Syveline Zuh Dang, Ndip Esther Ndip, Mirabelle Pandong Feguem, Dickson S. Nsagha

Research Article | published 21 Oct 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0004695

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 25 Oct 2025) [No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 25 Oct 2025) [No new digest content identified]

PLoS One

http://www.plosone.org/
[Accessed 25 Oct 2025]
[No new digest content identified]

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 25 Oct 2025] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 21, 2025 Vol. 122 no. 42 https://www.pnas.org/toc/pnas/122/42 [New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 9, September 2025 https://academic.oup.com/pnasnexus/issue/4/9 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 198 September 2025 https://www.sciencedirect.com/journal/preventive-medicine/vol/198/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

October 2025 Volume 292 Issue 2056 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

Public Health

Volume 246 September 2025 https://www.sciencedirect.com/journal/public-health/vol/246/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

Public Health Reports

Volume 140 Issue 4, July/August 2025 https://journals.sagepub.com/toc/phrg/140/4 [Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 12, October 2025

https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 21 Issue 4, October 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 25 Oct 2025] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 24 Oct 2025

<u>Protecting our frontline: vaccination policies for health care workers in the Americas</u> Original research | English

This paper explores vaccination policies for health care workers (HCWs) in effect in all 35 Pan American Health Organization (PAHO) countries plus the British territory of Anguilla to highlight strengths and challenges within the region and inform relevant policies and interventions.

Risk Analysis

Volume 45, Issue 9 Pages: 2467-2925 September 2025 https://onlinelibrary.wiley.com/toc/15396924/current [Reviewed earlier]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 25 Oct 2025] [No new digest content identified]

Royal Society Open Science

October 2025 Volume 12 Issue 10 https://royalsocietypublishing.org/toc/rsos/current [Reviewed earlier]

Science

Volume 390| Issue 6771| 23 Oct 2025 https://www.science.org/toc/science/current Editorial

Higher education fails at collective action

BY H. Holden Thorp 16 Oct 2025: 317

Science and Engineering Ethics

Volume 31, Issue 5 October 2025 https://link.springer.com/journal/11948/volumes-and-issues/31-5 [Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 821| 22 Oct 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

Scientific Reports

https://www.nature.com/srep/articles?type=article
[Accessed 25 Oct 2025]
[No new digest content identified]

Social Science & Medicine

Volume 380 September 2025 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 25 Oct 2025] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 5 October 2025 https://link.springer.com/journal/11017/volumes-and-issues/46-5 [Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 67 September—October 2025 https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/67/suppl/C [Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 10 Pages: 1025-1143 October 2025 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

Vaccine

Volume 65 24 October 2025

https://www.sciencedirect.com/journal/vaccine/vol/65/suppl/C [Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines

[Accessed 25 Oct 2025] Open Access Article

RSV Vaccination Programme for Older Adults: A Scotland-Wide Study on RSVpreF Vaccine Safety

by Lucy A. Cullen, Cheryl L. Gibbons, Ting Shi, Taimoor Hasan, Christopher Sullivan, Kimberly Marsh, Chris Robertson, Joanne Claire Cameron and Sam Ghebrehewet

Vaccines 2025, 13(11), 1088; https://doi.org/10.3390/vaccines13111088 - 24 Oct 2025

Abstract

Background/Objectives: Respiratory Syncytial Virus (RSV) is a common respiratory tract infection that accounts for significant morbidity and mortality, particularly among older adults. From 1 August 2024, the bivalent RSVpreF vaccine (Abrysvo®) was introduced in Scotland for eligible older adults. While clinical [...]

Open Access Article

Parents' Attitudes and Beliefs Towards Human Papillomavirus Vaccination

by Ivana Kotromanovic Simic, Darko Kotromanovic, Nika Lovrincevic Pavlovic, Jelena Kovačević, Marija Olujic, Danijela Nujic, Matea Matic Licanin, Ivon Matić, Jelena Sakic Radetic, Ilijan Tomas, Vlatko Kopic, Ivan Miskulin and Maja Miskulin

Vaccines 2025, 13(11), 1085; https://doi.org/10.3390/vaccines13111085 - 22 Oct 2025

Abstract

Background/Objectives: The Human Papillomavirus (HPV) is one of the most common causes of STIs, posing a significant public health problem. Today, the transmission of HPV can be very effectively prevented, making it important to vaccinate the target population at a young age. [...]

Open Access Article

Assessing Vaccine Confidence Using the Vaccine Hesitancy Scale Among Adolescent Girls and Young Women at Risk of HIV Acquisition Living in Uganda, Zambia, and South Africa by Nasimu Kyakuwa, Ali Ssetaala, Matt A. Price, Annet Nanvubya, Joel M. Abyesiza, Geofrey Basalirwa, Brenda Okech, Juliet Mpendo, Mubiana Inambao, Kawela Mumba-Mwangelwa, Chishiba Kabengele, Suzanna C. Francis, Pholo Maenetje, Ken Ondeng'e, Vinodh Edward, William Kilembe and Monica O. Kuteesa

Vaccines 2025, 13(11), 1083; https://doi.org/10.3390/vaccines13111083 (registering DOI) - 22 Oct 2025

Abstract

Background: Vaccine hesitancy (VH) remains a major threat to global health that can reverse the progress in tackling vaccine-preventable diseases. Vaccine uptake among adolescent Girls and young women (AGYW) is often low. We assessed VH using a validated scale among AGYW in Uganda, [...]

Value in Health

October 2025 Volume 28 Issue 10 p1461-1600 [Reviewed earlier]

World Development

Volume 194 October 2025

https://www.sciencedirect.com/journal/world-development/vol/194/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 25 Oct 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2510.19279 [pdf, other]

<u>Code Sharing in Healthcare Research: A Practical Guide and Recommendations for Good</u> Practice

<u>Lukas Hughes-Noehrer, Matthew J Parkes, Andrew Stewart, Anthony J Wilson, Gary S Collins, Richard D Riley, Maya Mathur, Matthew P Fox, Nazrul Islam, Paul N Zivich, Timothy J Feeney</u>

As computational analysis becomes increasingly more complex in health research, transparent sharing of analytical code is vital for reproducibility and trust. This practical guide, aligned to open science practices, outlines actionable recommendations for code sharing in healthcare research. Emphasising the FAIR (Findable, Accessible, Interoperable, Reusable) principles, the authors address common barriers and provide clear guidance to help make code more robust, reusable, and scrutinised as part of the scientific record. This supports better science and more reliable evidence for computationally-driven practice and helps to adhere to new standards and guidelines of codesharing mandated by publishers and funding bodies.

arXiv:2510.19196 [pdf, other]

<u>Integration of AI in STEM Education, Addressing Ethical Challenges in K-12 Settings</u> Shaouna Shoaib Lodhi, Shoaib Lodhi

Comments: This paper pursues three goals: (1) analyzing ethical challenges in AI-driven STEM education, (2) evaluating AI and ethics curricula for STEM relevance, and (3) proposing a research-based framework for responsible integration that bridges teacher readiness gaps and promotes equity through STEM-focused strategies

The rapid integration of Artificial Intelligence (AI) into K-12 STEM education presents transformative opportunities alongside significant ethical challenges. While AI-powered tools such as Intelligent Tutoring Systems (ITS), automated assessments, and predictive analytics enhance personalized learning and operational efficiency, they also risk perpetuating algorithmic bias, eroding student privacy, and exacerbating educational inequities. This paper examines the dual-edged impact of AI in STEM classrooms, analyzing its benefits (e.g., adaptive learning, real-time feedback) and drawbacks (e.g., surveillance risks, pedagogical limitations) through an ethical lens. We identify critical gaps in current AI education research, particularly the lack of subject-specific frameworks for responsible

integration and propose a three-phased implementation roadmap paired with a tiered professional development model for educators. Our framework emphasizes equity-centered design, combining technical AI literacy with ethical reasoning to foster critical engagement among students. Key recommendations include mandatory bias audits, low-resource adaptation strategies, and policy alignment to ensure AI serves as a tool for inclusive, human-centered STEM education. By bridging theory and practice, this work advances a research-backed approach to AI integration that prioritizes pedagogical integrity, equity, and student agency in an increasingly algorithmic world.

arXiv:2510.19869 [pdf, other]

<u>Challenges and Recommendations in Establishing National Human Diversity Genomic Projects</u>

Taras K. Oleksyk, Walter W. Wolfsberger, Karishma Chhugani, Yu-Ning Huang, Valerii Pokrytiuk, Khrystyna Shchubelka, Alex Zelikovsky, Bogdan Pasaniuc, Viorel Jinga, Octavian Bucur, Scott C. Edmunds, Heinner Guio, Zane Lombard, Brenna M. Henn, Andrei Lobiuc, Alexei Levitchi, Dumitru Ciorba, Viorel Bostan, Viorel Munteanu, Victor Gordeev, Christian P. Schaaf, Hoh Boon-Peng, Andrés Moreno Estrada, Mihai Covasa, Mihai Dimian, Ulykbek Kairov, Victoria M. Pak, Seow Shih Wee, Charleston W. K. Chiang, Emmanuel Nepolo, Matteo Pellegrini, Yosr Hamdi, Malak S. Abedalthagafi, Nicola Jane Mulder, Jazlyn Mooney, Javier E. Sanchez-Galan, Sandro José de Souza, Henriette Raventós, Marina Muzzio, Gabriela Chavarria-Soley, Serghei Mangul

Genomic approaches have revolutionized medical research, providing valuable insights into human physiology and disease. Despite major benefits from large collections of genomes, the lack of diversity in genomic data represents a significant challenge for advancing biomedical discovery and accessible health solutions worldwide. Establishing a national genomic project is not a one-size-fits-all endeavor, as each country presents distinct challenges and opportunities. We identify challenges in the way of obtaining and publishing data from Whole Genome Sequencing (WGS) of people in various countries, discuss the progress made by some in their efforts to study their genetic diversity, and assess the most common issues. We recognize that a successful national genome database requires addressing several major issues, including the variable awareness of the recent developments in genomics among government officials, healthcare administrators, and policymakers, the absence of regulations, and ethical considerations, the challenges in securing funding, establishing legal frameworks, and building the necessary infrastructure. By assembling a diverse team of experts across 19 countries, we aim to provide a balanced approach in our recommendations to establish national projects. Our study acknowledges and addresses major intricacies and nuances specific to various settings and regions while presenting diverse opinions of scientists from both high-resource and low-resource countries contributing to a more inclusive and globally relevant framework for advancing genomic research and its applications.

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 25 Oct 2025] [Filter: All articles]

[No new digest content identified]

medRxiv

https://www.medrxiv.org/content/early/recent

[Accessed 25 Oct 2025] [Filter: All articles]

Burden, Risk Factors, and Clinical Outcomes of Pediatric Malaria in Nigeria: A Systematic

Review and Meta-Analysis Protocol

Ibrahim Rasheed Olayinka, Jubril Abdulkareem, Amudalat Issa, Michael Abel Alao

medRxiv 2025.10.22.25338582; doi: https://doi.org/10.1101/2025.10.22.25338582

<u>Infectious disease modeling for public health practice: projections, scenarios, and uncertainty in three phases of outbreak response</u>

Andrew F. Brouwer, Marisa C. Eisenberg, Natalie E. Dean, Harry Hochheiser, Philip Huang, Joseph R. Coyle, Lior Rennert

medRxiv 2025.10.20.25338175; doi: https://doi.org/10.1101/2025.10.20.25338175

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 25 Oct 2025] article / Open Letter awaiting peer review

<u>Mechanistic yellow fever modelling under climate change in Brazil and beyond:</u> <u>Information gaps and future steps</u>

[version 1; peer review: awaiting peer review]

Authors Livia Abdalla, Angélica S. da Mata, Keith J Fraser, Sally Jahn, Eduardo Krempser, Adriano Pinter, Alessandro Pecego Martins Romano, Antônio Ralph Medeiros-Sousa, Daniel Garkauskas Ramos, Helio Junji Shimozako, Luis Filipe Mucci, Luiz Antonio Costa Gomes, Luiz Carlos Junior Alcantra, Ramon Silva Oliviera, Rodrigo Otávio Pereira Sayago Soares, Vinicius Pereira Feijó, Douglas Augusto, Marcia Chame, Katy A M Gaythorpe

Funders Wellcome Trust | Medical Research Council | CNPq/Fapemig

Peer Reviewers Invited

Published 24 Oct 2025

Abstract

Yellow fever (YF) remains a significant public health threat in tropical regions, particularly in South America and Africa. The combined forces of climate change, land-use, urbanisation, globalisation, and insufficient surveillance and health infrastructure are driving the re-emergence and expansion of YF into new areas. While mathematical models have been used to estimate transmission risk, disease burden, and the impact of vaccination, there remains a crucial gap in mechanistic models that explicitly capture how climate and environmental changes directly influence YF transmission. To address this gap, we convened a workshop in Brazil as part of the Vaccine Impact Modelling Consortium's Climate Change programme, bringing together national and international experts. The workshop aimed to present current modelling approaches, identify key knowledge gaps, and develop strategies to improve data collection and model applicability. Discussions highlighted major uncertainties regarding vectors, non-human primates, surveillance sensitivity, vaccination, and climatic and environmental drivers. This paper synthesises the outcomes of the workshop, including priority areas for future research and recommendations for advancing mechanistic YF modelling in the context of climate change, with a focus on both Brazil and broader tropical regions.

* * * *

Brookings [to 25 Oct 2025]

http://www.brookings.edu/

Research, Events

No new digest content identified.

Center for Global Development [25 Oct 2025]

https://www.cgd ev.org/

All Research

CGD NOTE

PEPFAR's Missing Data: Why Transparency Matters More Than Ever

Ramona Godbole

October 20, 2025

The Trump administration has promised to preserve this lifesaving assistance. But since the start of the year, there has been no way to confirm if assistance is still reaching those who need it.

Chatham House [to 25 Oct

2025]

https://www.chathamhouse.org/

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [25 Oct 2025]

https://www.cfr.org/media/news-releases

New Releases [Selected]

No new digest content identified.

CSIS [25 Oct 2025]

https://www.csis.org/

Reports [Selected]

No new digest content identified.

McKinsey Global Institute [25 Oct 2025]

https://www.mckinsey.com/mgi/overview

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 25 Oct 2025]

https://odi.org/en/publications/

Publications [Selected]

No new digest content identified.

Pew Research Center [25 Oct 2025]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 25 Oct 2025]

https://www.rand.org/pubs.html Published Research [Selected]

Research Oct 24, 2025

China's Global Health Activities in Africa: Historical Perspectives and Case Studies

The authors examine the People's Republic of China's global health activities and policies in Africa since the 1960s. They report case studies of two nations that have received health aid from China and offer analysis and policy recommendations.

Commentary Oct 23, 2025

Rebuilding Gaza—from Camps to Communities

With most of Gaza destroyed, finding homes for 2.2 million people will require a new approach. Future-oriented camps, incremental rebuilding, and new neighborhoods could shelter Gazans now while laying the groundwork for lasting recovery and stability.

Commentary Oct 22, 2025

Needed: Blueprint for a U.S. Health System Overhaul

The U.S. health system is ill-equipped to meet patient and community needs. A patient-centered overhaul should prioritize health education and disease prevention, provide care to patients where and when it is most convenient for them, leverage technology, increase access and capacity, and curb costs.

Research Oct 20, 2025

<u>Protecting Biological Materials and Services from Misuse: Opportunities for Access Monitoring and Control</u>

The authors explore critical points within the biological supply network that bad actors might exploit to develop biological weapons. The authors develop recommendations for enhancing data collection, regulatory oversight, and threat mitigation.

Urban Institute [to 25 Oct 2025]

https://www.urban.org/research

New Research Publications - Selected

World Economic Forum [to 25 Oct 2025]

https://agenda.weforum.org/press/

Media [Selected]

10 Transformative Innovations for Climate Action and Planetary Health

News 15 Oct 2025

- New report spotlights 10 tech solutions to accelerate climate action from carbon-locking concrete and sustainable desalination for arid regions to cars that feed the electric grid.
- The research maps a wave of emerging technologies with significant potential to tackle climate disruption head-on, from droughts to methane leaks to rising seas.
- The report focuses on food, water, energy and materials key systems for a stable planet showing how science can safeguard planetary health and curb destructive human activity.
- Read the report <u>here</u>. Follow the Annual Meeting of the Global Future Councils and the Annual Meeting on Cyber Security 2025 here and on social media using #AMGFCC25

::::::

Public Consultations/Call for Inputs/Call for Papers

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01/2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States) Regulatory Chair: Dr. Christian Roes (EC, Europe) Date of Step 2b: 25 June 2025 Status: Step 3

<u>Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket;</u> <u>Request for Comments</u>

A Notice by the Food and Drug Administration on 10/02/2025 **Comments: November 5, 2025** DATES: The meeting will be held on virtually on November 13, 2025, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET).

SUMMARY:

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the Committee is to provide advice and recommendations to FDA on pediatric regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Comments received on or before November 5, 2025, will be provided to the Committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

The docket number is FDA-2025-N-1246. The docket will close on November 12, 2025.

National Institute of Mental Health, Interagency Autism Coordinating Committee Call for Committee Membership Nominations

A Notice by the National Institutes of Health on 09/24/2025 **Nominations due November 10, 2025.**

SUMMARY:

The Office of the Secretary of the Department of Health and Human Services (HHS) is seeking nominations of individuals to serve as non-federal public members on the Interagency Autism Coordinating Committee (IACC).

The Office of National Autism Coordination (ONAC) of the National Institute of Mental Health, National Institutes of Health is assisting the Department in conducting an open nomination process. Appointments of non-federal public members to the committee shall be made by the Secretary of Health and Human Services.

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends 11/24/2025.**

Docket No. FDA-2017-D-6159 :: 21 pages SUMMARY:

This guidance provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with our recommendations on the expedited development and review of these therapies, including as provided under section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3033 of the 21st Century Cures Act (Cures Act). Under section 506(q) of the FD&C Act, a regenerative medicine therapy can be designated as a regenerative advanced therapy if it meets certain criteria. FDA refers to such designation as "regenerative medicine advanced therapy" (RMAT) designation (see section III.C of this document). This guidance describes the expedited programs available to sponsors of regenerative medicine therapies for serious conditions, including those products designated as RMATs. To that end, the guidance provides information about the provisions in the Cures Act regarding the use of the accelerated approval pathway for regenerative medicine therapies that have been granted designation as an RMAT. Finally, the guidance describes considerations in the clinical development of regenerative medicine therapies and opportunities for sponsors of such products to interact with the Center for Biologics Evaluation and Research (CBER) review staff. As a general matter, this guidance addresses regenerative medicine therapies regulated by CBER as biological products under the FD&C Act, section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262), and applicable regulations.

<u>Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations; Draft Guidance for Industry; Availability</u>

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends** (11/24/2025.

Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/23/2025. Comment period ends 12/22/2025.

Docket No. FDA-2025-D-0918

* * *

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u> and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.